| dc.identifier.citation | Alfirevic A, Park BK, and Pirmohamed M, Pharmacogenetics of Adverse Drug Reactions dalam Pharmacogenetics, Hall, IP & Pirmohamed M, Taylor &Franchise,2006. New York Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice”. Pharmacol. Rev. 2006. 58 (3): 521–90. Klotz, U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. ClinPharmacokinet .2007. 46 (4): 271–9. Lullman, H , Hein L, Mohr K & Bieger D, Colr atlas of pharmacology, 2005, ebook Weber, W.W. Pharmacogenetics. 2008. Oxford University Press, Inc, New York. Angulo, AMG, Hortobágyi, GN and Esteva, FJ, Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer. The Oncologist. 2006 vol. 11 no. 8 857-867 Cavallari, L.H., & Lam, Y.W.F., dalam DiPiro,J.T., Talbert,L.I., Yee,G.C., Matzke,G.R., Wells, B.G., Possey, LM., 2005. Pharmacotherapy: A Pathophysiologic Approach. pp. 75-90. Mc Graw Hill Companies Inc., New York Weber, W.W., 2008, Pharmacogenetics, Oxford University Press, Inc, New York. Ambudkar, S.V., Kimchi-Sarfaty, C., Sauna, Z.E., Gottesman, M.M. P-glycoprotein: from Genomics to Mechanism. Oncogene. 2003.22: 7468-7485 Ayrton, A.; Morgan, P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001. 31 (89): 469 497 Balram, C.Frequency of C3435T Single Nucleotide MDR1 Genetic Polymorphism in an Asian Population: Phenotypic-Genotypic Correlates. Br.J.Clin. Pharmacol. 2003. 56(1): 78-83 Beitelshees, A.L., Zineh, I., Yarandi, H.N., Pauly, D.F., Johnson, J.A. Influence of Phenotype and Pharmacokinetics on -blocker Drug Target Pharmacogenetics. The Pharmacogen J. 2006. 6: 174-178 Brinkmann, U., & Eichelbaum, M. Polymorphisms in The ABC Drug Transporter Gene MDR1. The pharmacogenomics J. 2001. 1(1): 59- 64 Cascorbi, I., Drakoulis, N., Brockmoller, J.,Maurer, A., Sperling, K., and Roots, I. ArylamineN-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals, Correlation with phenotypic activity. Am. J. Hum. Genet. 1995. 57: 581 Cavallari, L.H., & Lam, Y.W.F., dalam DiPiro,J.T., Talbert,L.I., Yee,G.C., Matzke,G.R., Wells, B.G., Possey, LM., 2005. Pharmacotherapy: A Pathophysiologic Approach. pp. 75-90. Mc Graw Hill Companies Inc., New York Cordon-Cardo, C., O’Brien, J.P., Boccia J., 1990. Expression of the Multidrug Resistance Gene Product (P-glycoprotein) in Human Normal and Tumour Tissues. J. Histochem Cytochem. 38: 1277–1287 Dean, M., Rzhetsky, A., Allikmets, R. The Human ATP-Binding Cassette (ABC) Transporter Superfamily. Genome Res. 2001.11(7): 1156- 1166 Drozdzik, M.; Bialecka, M.; Mysliwiec, K.; Honczarenko, K.;Stankiewicz, J. and Sych, Z. Pharmacogenetics.2003. 13(5), 259-263 Fellay, J.; Marzolini, C.; Meaden, E.R.; Back, D.J.; Buclin, T.; Chave, J.P.; Decosterd, L.A. et al. Response to antiretroviral treatment in HIV34 Farmakogenetik Konsep Dasar & Implikasi Klinis 1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet.2002. 359(9300), 30-36. Fojo, A.T., Ueda, K., Slamon, D.J.Expression of a Multidrug-Resistance Gene in Human Tumours and Tissues. Proc. Natl. Acad Sci. USA. 1987.84: 265–269 Furuno, T.; Landi, M.T.; Ceroni, M.; Caporaso, N.; Bernucci, I.;Nappi, G. et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics. 2002. 12(7),529-534. Hankø E, Tommarello S, Watchko JF, Hansen TW. Administration of Drugs Known to Inhibit P-glycoprotein Increases Brain Bilirubin and Alters the Regional Distribution of Bilirubin in Rat Brain. Pediatr Res. 2003. 54(4): 441-5 Higgins, C.F. ABC Transporters: From Microorganisms to Man. Annu. Rev. Cell Biol. 1992. 8: 67–113 Hoffmeyer, S., Burk, O., Von Richter, O. Functional Polymorphism of the Human Multidrug Resistence Gene: Multiple Sequence Variations and Correlation of One Allele with P-glycoprotein Expression and Activity Invivo. Proc. Natl. Acad. Sci. U S A.2003. 97(7): 3473-8 Hong, L.Y., Hua, W.Y., Yan,L., Ling, Y. MDR1 Gene Polymorphisms and Clinical Relevance. Acta Gen. Sinica. 2006. 33 (2): 93–104 Hwan Oh, J., Sook Dong, M., Gyu Choi, M. Effects of CYP2C19 and MDR1 Genotype on the Eradication Rate of Helicobacter Pylori Infection by Triple Therapy with Pantoprazole, Amoxycillin and Clarithromycin. J. of Gastro and Hep. 2009. 24: 294–298 Iida A, Saito S, Sekine S,Mishima C, Kondo K, Kitamura Y, Harigae S, Osawa S, and Nakamura Y. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides and three NADH:ubiquinone oxidoreductase flavoproteins. J Hum Genet.2001. 46:668–683. Jamroziak, K., Balcerczak, E., Mlynarski, W., Mirowski, M., Robak, T. Distribution of Allelic Variants of Functional C3435T Polymorphism of Drug Transporter MDR1 Gene in a Sample of Polish Population. Pol. J. Pharmacol. 2002.54: 495–500 Farmakogenetik pada Drugs Transporter Genes 35 Juliano, R.L, Ling, V., A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants. Biochim Biophys Acta. 1976. 455(1): 152-62 Kerb R, Hoffmeyer S, and Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenetics.2001. 2:51–64. Klein, I., Sarkadi, B., Varadi, A. An Inventory of the Human ABC Proteins. Biochim Biophys Acta. 1999. 1461(2): 237-262 Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J,Taylor T, Clark AG, Herskowitz I, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. J Hum Genet.2002. 46:668–683. Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., Mc Connell, T.S. Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-glycoprotein, MRP1, and LRP in acute Myeloid Leukemia: a Southwest Oncology Group Study. Blood. 1999. 94: 1086–99 Li, Y., Wang, Y., Sun, J., 2006. Distribution of Functional MDR1C3435T Polymorphism in th Han Population in China. Swiss Med WKLY. 136: 377-378 Licinio, J., & Wong, M.L. Pharmacogenomics: The Search for Individualized Therapies. Wiley, Germany. 2002. 179-213 Lown, K.S., Mayo, R.R., Leitchman, A.B. Role of Intestinal P-glycoprotein (MDR 1) in Interpatient Variation in the Oral Bioavailability of Cyclosporin A. Clin Pharmacol Ther. 1997. 62: 248–260 Mayatepek E, Nezu J, Tamai I, Oku A, Katsura M, Shimane M, and Tsuji A. Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency. Hum Mutat.2000. 15:118. Mitchell, E. T., Lalitha, P., Diane, E., and Iliana, A., 2005. Funtional Assessment of Multiple P-glycoprotein (P-GP) Probe Substrates: Influnce of Cell Line and Modulator Concentration on P-GP Activity. Drug Metab. Dispos. 33(11): 1679-1687 36 Farmakogenetik Konsep Dasar & Implikasi Klinis Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y,Koizumi A, Shoji Y, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet.1999. 21:91–94. Pechandova, K., Budzoka, H., Slanar, O. Pholimorphism of the MDR-1 Gene in the Czech Population. Folia biologica. 2006.52: 184-189 Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M, Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., Kasuga, M., Okumura, K., MDR1 Genotype-Related Pharmacokinetics of Digoxin after Single Oral Administration in Healthy Japanese Subjects. Pharm. Res.2001.18(10): 1400-4 Schaich, M., Kestel, L., Pfirrmann, M., 2010. A MDR1 (ABCB1) Gene Single Nucleotide Polymorphism Predicts Outcome of Temozolomide Treatment in Glioblastoma Patients. Oxford J. med. annals of oncol. 2010. 20(1): 175-181 Schinkel, A.H., Smitt, J.J., Van Tellingen, O. Disruption of the Mouse MDR1a P-glycoprotein Gene Leads to a Deficiency in the Blood–Brain Barrier and to Increased Sensitivity to Drugs. Cell. 1994. 77: 491–502 Shapiro, A.B., Fox, K., Lam, P., Ling, V. Stimulation of P-glycoprotein- Mediated Drug Transport by Prazosin and Progesterone. Evidence for a Third Drug-Binding Site. Eur. J. Biochem. 1999. 259(3): 841-50. Silverman, J.A., & Schrenk, D. Hepatic Canalicular Membrane 4: Expression of the Multidrug Resistance Genes in the Liver. FASEB J. 1997. 11: 308–313 Sutrisna. EM, Pengaruh polimorfisme Multi drugs resistant1C3435T dan Cytochrome 3A4*1G terhadap kadar rifampisin dan konversi bakteri tahan asam pada penderita tuberculosis paru suku Jawa. 2011, Laporan desertasi. Suzuki H and Sugiyama Y .Transporters for bile acids and organic anions, in Membrane Transporters as Drug Targets (Sadee W and Amidon G eds) .1999. pp. 387–439, Kluwer Academic/Plenum Publishing Co, New York. Tanabe, M., Iere, I., Inoue, K., 2001. Expression of P-glycoprotein in Human Placenta: Relation to Genetic Polymorphism of the Multidrug Resistance (MDR)-1 Gene. J.P.E.T. 2001.297(3): 1137-1143 Farmakogenetik pada Drugs Transporter Genes 37 Tang, K., Wong, L.P., Lee, E.J., Chong, S.S., Lee, C.G. Genomic Evidence for Recent Positive Selection at the Human MDR1 Gene Locus. Hum. Mol. Genet. 2004.13 (8): 783-797 Thiebaut, F., Tsuruo, T., Hamada, H. Cellular Localisation of the Multidrug Resistance Gene Product P-glycoprotein in Normal Human Tissues. Proc. Natl. Acad. Sci. USA. 1987.84: 7735–7738 Tirona RG, Leake BF, Merino G, and Kim RB. Polymorphisms in oatp-c Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem.2001. 276:35669–35675. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Archives of Neurology. 2012. 69(4):445–451. | in_ID |
